KIT and ovarian carcinoma: A recent phase I/II trial of olaparib in combination with the VEGF and c-kit inhibitor, cediranib, in patients with recurrent ovarian or metastatic triple-negative breast cancer (but unknown BRCA status) demonstrated haematological DLTs (grade 4 neutropaenia and thrombocytopaenia) and anticipated class toxicities (grade 3/4 neutropaenia, hypertension, fatigue, anorexia, nausea and asymptomatic pulmonary embolism) with an unconfirmed response rate of 56% in ovarian cancer patients (Liu et al, 2011).